Pfizer could score $515 million from the sale of a schizophrenia drug By: New York Business Journal via Business Journals March 13, 2018 at 12:24 PM EDT The sale allows Cambridge, Massachusetts-based Biogen to develop a new treatment for cognitive impairment. Read More >>
